IP Library › Granted Patent US 10,336,816
Granted Patent B2
US 10,336,816 · App. 15/547,523 · Granted Jul 2, 2019

Phage-displayed single-chain variable fragment library

Inventors: An-Suei Yang (Emeryville, CA); Hong-Sen Chen (Taipei, TW); Ing-Chien Chen (Taipei, TW); Chao-Ping Tung (Taipei, TW); Shin-Chen Hou (Taichung, TW); Chung-Ming Yu (Taipei, TW); Chi-Kai Yang (Taipei, TW); Yi-Kai Chiu (Taipei, TW)
Assignee: Academia Sinica
C07K16/005C07K16/1018C07K16/18C07K16/22C07K16/245C07K16/2803C07K16/2827C07K16/2863C07K16/2887C07K16/32C12N15/1037C07K2317/34C07K2317/622C07K2317/76C07K2317/77C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,336,816
App. No.
15/547,523
Granted
Jul 2, 2019
Kind
B2
Abstract

Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, that comprised a plurality of phage-displayed scFvs characterized with (1) a specific CS combination; (2) a specific distribution of aromatic residues in each CDR; and (3) a specific sequence in each CDR. The present scFv library could be used to efficiently produce different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.

Claims (7)

1. A phage-displayed single-chain variable fragment (scFv) library comprising a plurality of phage-displayed scFvs, wherein each of the plurality of phage-displayed scFvs comprises a first heavy chain complementarity determining region (CDR-H1), a second heavy chain CDR (CDR-H2), a third heavy chain CDR (CDR-H3), a first light chain CDR (CDR-L1), a second light chain CDR (CDR-L2), and a third light chain CDR (CDR-L3),

wherein,

each of the CDR-H1, CDR-L2 and CDR-L3 has a type 1 canonical structure (CS), whereas each of the CDR-H2 and CDR-L1 has a type 2 CS; and

each of the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 has a distribution of aromatic residues that is similar to the distribution of aromatic residues in the corresponding CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 of a natural antibody; wherein

the CDR-L1 is encoded by a first coding sequence comprising the nucleic acid sequence of any of SEQ ID NOs: 2-10, the CDR-L2 is encoded by a second coding sequence comprising the nucleic acid sequence of any of SEQ ID NOs: 11-14, the CDR-L3 is encoded by a third coding sequence comprising the nucleic acid sequence of any of SEQ ID NOs: 15-22, the CDR-H1 is encoded by a fourth coding sequence comprising the nucleic acid sequence of any of SEQ ID NOs: 23-26, the CDR-H2 is encoded by a fifth coding sequence comprising the nucleic acid sequence of any of SEQ ID NOs: 27-28, and the CDR-H3 is encoded by a sixth coding sequence comprising the nucleic acid sequence of any of SEQ ID NOs: 29-106.

2. The phage-displayed scFv library of claim 1 , wherein the phage is a M13 phage or a T7 phage.

3. The phage-displayed scFv library of claim 1 , wherein at least one of the plurality of phage-displayed scFvs is specific for a protein antigen selected from the group consisting of human epidermal growth factor receptor 2 (HER2), maltose-binding protein (MBP), bovine serum albumin (BSA), human serum albumin (HSA), lysozyme, interleukin-1 beta (IL-1β), hemagglutinin of influenza virus (HA), nucleoprotein of influenza virus (NP), vascular endothelial growth factor (VEGF), epidermal growth factor receptor 1 (EGFR1), epidermal growth factor receptor 3 (EGFR3), glucagon receptor, human DNase I, programmed death-ligand 1 (PD-L1), sialic acid binding Ig-like lectin 3 (SIGLEC 3), fragment crystallizable region (Fc region) of immunoglobulin G (IgG), and rituximab.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2017
From: YANG, AN-SUEI; CHEN, HONG-SEN; CHEN, ING-CHIEN; TUNG, CHAO-PING; HOU, SHIN-CHEN; YU, CHUNG-MING; YANG, CHI-KAI; CHIU, YI-KAI
To: ACADEMIA SINICA
Reel/Frame 043362/0407 →
Continuity (2)
Provisional Application 62120352 · Feb 24, 2015
Related Publication 20180009877A1 · Jan 11, 2018